Clinical trials
Advanced Bladder Cancer clinical trials
Below are recruiting advanced bladder cancer clinical trials, each written for real people, not researchers. We’re tracking 259 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07561723RecruitingPhase 1
IMP3 Vaccine for Advanced Lung Cancer After Treatment Failure
This study tests a new vaccine designed to help your immune system fight advanced lung cancer that has not responded to standard treatments. The vaccine targets a protein called IMP3 found in your cancer cells.
Chengdu, SichuanAges 18 years+ - NCT05758116RecruitingPhase 2
Tislelizumab after radiation to stop lung cancer from growing
This Phase 2 trial studies tislelizumab (an immune therapy) given after you finish radiation or combined chemotherapy-radiation for stage III non-small cell lung cancer. It aims to keep the cancer from coming back or growing by helping your immune system stay active.
BeijingAges 18 years+ - NCT07231068RecruitingPhase 1/Phase 2
Dositinib tablets for advanced lung cancer with EGFR mutation
This trial tests a new targeted therapy, Dositinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to earlier EGFR-targeted drugs. It aims to find the best dose and see how well it shrinks tumors.
BeijingAges 18–75 - NCT06444815RecruitingPhase 1
Study of VET3-TGI for advanced solid tumors
This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.
Los Angeles, CaliforniaAges 18 years+ - NCT06359847RecruitingPhase 2
ST-1898 for advanced thyroid cancer that no longer responds to iodine therapy
This trial tests an experimental drug called ST-1898 for people with advanced thyroid cancer that has stopped responding to radioactive iodine treatment and has progressed after at least one targeted therapy. It aims to see if ST-1898 can shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06860971RecruitingPhase 3
AL2846 capsule vs placebo for advanced thyroid cancer
This study tests a new oral capsule (AL2846) against a placebo in people with advanced thyroid cancer that no longer responds to radioactive iodine. The goal is to see if AL2846 can slow or stop cancer growth.
Hefei, AnhuiAges 18–75 - NCT06041503RecruitingPhase 2
Treating rare bladder and testicular cancers with targeted therapy
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) for people with certain rare cancers of the urinary tract or testicles. The goal is to see if these treatments can shrink tumors or stop them from growing.
Bethesda, MarylandAges 18–120 - NCT03454035RecruitingPhase 1
Ulixertinib and palbociclib for advanced pancreatic and solid cancers
This early-phase study tests ulixertinib plus palbociclib to treat advanced cancers that have spread or cannot be removed by surgery. It aims to find the right dose and see whether this combination can shrink tumors or slow their growth, especially in metastatic pancreatic cancer.
Chapel Hill, North CarolinaAges 18–99 - NCT05473156RecruitingPhase 1/Phase 2
Study of AP203 for advanced solid tumors that grew despite treatment
This early-phase study tests AP203 (an investigational treatment) to see if it is safe and to look for signs it can shrink or control certain advanced cancers. The study includes a dose-finding part for many solid tumors, and a second part focused on specific lung and head/neck cancers that previously received PD-1/PD-L1 therapy.
TaipeiAges 18 years+ - NCT07278479RecruitingPhase 1/Phase 2
Study of a targeted radiation therapy for small cell lung cancer
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
Atlanta, GeorgiaAges 18 years+ - NCT07218380RecruitingPhase 3
Study of Vepugratinib for advanced bladder or urinary tract cancer
This trial tests an experimental drug called Vepugratinib for people with advanced urinary tract cancer that has a specific change in the FGFR3 gene. It may be an option if you haven't had other treatments for advanced cancer and are looking for a new approach.
Huntsville, AlabamaAges 18 years+ - NCT06823427RecruitingPhase 2
9MW2821 with or without immunotherapy for advanced urothelial cancer
This trial tests a combination of an investigational drug (9MW2821) with an immunotherapy (toripalimab) against 9MW2821 alone for people with advanced urothelial cancer who have not yet received any systemic treatment. The goal is to see if the combination works better than the single drug.
Changsha, HunanAges 18–80 - NCT06218810RecruitingPhase 2
Combination therapy for advanced MSS, RAS-mutated colorectal cancer
This trial tests a new combination of three medicines for people with a certain type of advanced colorectal cancer that has not been treated before. It aims to see if adding an immunotherapy drug (Cadonilimab) to standard chemotherapy and a targeted therapy (Bevacizumab) can help shrink tumors and delay disease progression.
ShanghaiAges 18–75 - NCT07197580RecruitingPhase 3
Study of a targeted radiation therapy for advanced kidney cancer
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
Sydney, New South WalesAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65 - NCT04622423Recruiting
Advanced therapies for colon or pancreas liver metastases
This study tests advanced treatments for cancer that has spread to the liver, either from colon cancer or pancreatic cancer. It may help by targeting liver tumors using treatment plans and, for some participants, liver tissue samples.
Milan, MilanAges 18 years+ - NCT05614739RecruitingPhase 1
Study drug for cancers with an FGFR3 gene change
This Phase 1 trial tests LOXO-435 in people with solid tumors that have an FGFR3 pathway gene alteration. It may help shrink or control cancer by targeting this specific gene change.
Tucson, ArizonaAges 18 years+ - NCT06728189RecruitingPhase 1
CD70-targeted CAR-NKT cells for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
BeijingAges 18–75 - NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT06157996RecruitingPhase 2
Lenvatinib, Tislelizumab, and CapeOX for advanced stomach cancer
This trial tests a combination of three drugs (lenvatinib, tislelizumab, and CapeOX chemotherapy) as the first treatment for advanced stomach or gastroesophageal junction cancer that is PD-L1 positive and has a low TMEscore. The goal is to see if this combination helps control the cancer better than standard treatments.
Guangzhou, GuangdongAges 18 years+ - NCT04879121RecruitingPhase 2
Larotrectinib for tumors with extra NTRK gene copies
This trial studies larotrectinib, a targeted medicine, in people with solid tumors that have extra copies (amplification) of the NTRK1, NTRK2, or NTRK3 gene. It’s for cancers that have already been treated with standard options or where standard options are unlikely to help.
Houston, TexasAges 16 years+ - NCT06161532RecruitingPhase 2
Sacituzumab govitecan with or without atezolizumab for rare GU cancers
This trial is testing a drug called sacituzumab govitecan, sometimes combined with atezolizumab (an immunotherapy), for rare cancers of the bladder, urinary tract, kidney, or penis. The goal is to see if these treatments work well for people whose cancers have not responded to other options.
Bethesda, MarylandAges 18–120 - NCT05786716RecruitingPhase 2/Phase 3
Trastuzumab plus pertuzumab for HER2-mutated cancers
This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.
BelfastAges 12 years+
Hear when a new Advanced Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced bladder cancer?
- Yes. Clin2 currently lists 259 recruiting advanced bladder cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced bladder cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced bladder cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.